Table 1 Demographic data and baseline characteristics

Female^a

59 (93.7)

34 (97.1)

25 (89.3)

0.31

Age, years^b

62.4 (±11.6)

64.4 (± 10.8)

59.9 (± 12.4)

0.13

DcSSc^a

10 (15.9)

4 (11.4)

6 (21.4)

0.31

Time from first symptom, years^b

18.6 (± 12.3)

19.6 (±11.2)

17.2 (± 13.7)

0.29

Time from first non-RP symptom, years^b

10.5 (± 8.9)

9.7 (±9.4)

11.5 (± 8.2)

0.21

ACR/EULAR 2013 classification criteria^a

61 (96.8)

34 (97.1)

27 (96.4)

1.0

Telangiectasias^a

59 (93.7)

33 (94.3)

26 (92.9)

1.0

Digital ulcers^a

35 (55.6)

20 (57.1)

15 (53.6)

0.77

Scleroderma renal crisis^a

2 (3.2)

2 (5.7)

0 (0)

0.49

Interstitial lung disease^a

32 (50.8)

19 (54.3)

12 (42.9)

0.45

Cardiac involvement^a

26 (41.3)

17 (48.6)

9 (32.1)

0.18

Antinuclear antibodies^a

62 (98.4)

34 (97.1)

28 (100)

1.0

 ACA^a

34 (54.0)

23 (65.7)

11 (39.3)

0.03

 Anti-Scl-70^a

12 (19.0)

3 (8.6)

9 (32.1)

0.01

 Nucleolar IIF pattern^a

4 (6.3)

3 (8.6)

1 (3.6)

0.62

Arterial hypertension^a

27 (42.9)

14 (40)

13 (43.4)

0.60

Dyslipidaemia^a

15 (23.8)

6 (17.1)

9 (32.1)

0.16

Diabetes mellitus^a

0 (0)

0 (0)

0 (0)

NA

Immunosuppressant therapy^a

25 (39.7)

8 (22.9)

17 (60.7)

<0.01

 Prednisone^a

19 (30.2)

7 (20.0)

12 (40.9)

0.04

 Sodium mycophenolate^a

7 (11.1)

1 (2.9)

6 (21.4)

0.03

 Azathioprine

3 (4.8)

0 (0)

3 (10.7)

0.08

 IV cyclophosphamide^a

12 (19.0)

3 (8.6)

9 (32.1)

0.01

Calcium channel blocker^a

33 (52.4)

14 (40.0)

19 (67.9)

0.02

Specific vasodilator therapy^a

13 (20.6)

7 (20.0)

6 (21.4)

0.88

 IV prostanoids^a

1 (1.6)

1 (2.9)

0 (0)

1.0

 ERA^a

10 (15.9)

5 (14.3)

5 (17.9)

0.74

 PDE5 I^a

5 (7.9)

2 (5.7)

3 (10.7)

0.64